&nbsp;

Drugs Used:

Quick Link(s):

Regimen Monograph

Nov 2024

Regimen

FC(PO)+R

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia

ODB Limited Use

fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)

ODB Limited Use

fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

Drugs Used:

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

FC(PO)

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

ODB Limited Use

fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)

ODB - General Benefit

cyclophosphamide - oral tablets

Drugs Used:

fludarabine,

cyclophosphamide

Quick Link(s):

Regimen Monograph

Jun 2019

Regimen

FLUD(PO)+R

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Second Line - Chronic Lymphocytic Leukemia

ODB Limited Use

fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)

ODB Limited Use

fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Previously Untreated Chronic Lymphocytic Leukemia

Drugs Used:

riTUXimab,

fludarabine,

riTUXimab (subcut) (PDRP prior authorization)

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

BORTDEXALENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Without Intent for Stem Cell Transplantation

ODB Limited Use

ODB - General Benefit

dexamethasone

Drugs Used:

bortezomib (PDRP prior authorization),

lenalidomide,

dexamethasone

Quick Link(s):

Regimen Monograph

Dec 2023

Regimen

BORTLENA(LD)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB Limited Use

lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or has not experienced progression while on a lenalidomide-based regimen in a treatment or maintenance setting, according to clinical criteria

Drugs Used:

bortezomib (Unfunded),

lenalidomide